Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Interest & Investment Income (2023 - 2025)

CG Oncology (CGON) has disclosed Interest & Investment Income for 3 consecutive years, with $7.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest & Investment Income rose 19.2% year-over-year to $7.4 million, compared with a TTM value of $29.9 million through Dec 2025, up 12.42%, and an annual FY2025 reading of $29.9 million, up 12.42% over the prior year.
  • Interest & Investment Income was $7.4 million for Q4 2025 at CG Oncology, roughly flat from $7.4 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $7.9 million in Q3 2024 and bottomed at $771000.0 in Q2 2023.
  • Average Interest & Investment Income over 3 years is $5.3 million, with a median of $6.6 million recorded in 2024.
  • The sharpest move saw Interest & Investment Income surged 800.52% in 2024, then dropped 5.97% in 2025.
  • Year by year, Interest & Investment Income stood at $2.8 million in 2023, then soared by 122.72% to $6.2 million in 2024, then increased by 19.2% to $7.4 million in 2025.
  • Business Quant data shows Interest & Investment Income for CGON at $7.4 million in Q4 2025, $7.4 million in Q3 2025, and $7.3 million in Q2 2025.